Seizure prophylaxis in pneumococcal meningitis, cohort study.

Area of Science:

• Neurology
• Infectious Diseases
• Pharmacology

Background:

• Pneumococcal meningitis, an infection of the brain's covering, historically had high mortality.
• While antibiotics and corticoids improve survival, complications like seizures remain significant sequelae.
• Seizures are a frequent complication impacting patient recovery and prognosis.

Purpose of the Study:

• To assess the incidence of seizures as a complication of pneumococcal meningitis.
• To evaluate the potential of antiseizure medication (ASM) prophylaxis in preventing these seizures.
• To determine the impact of ASM prophylaxis on patient outcomes.

Main Methods:

• Retrospective analysis of a prospective database of community-acquired pneumococcal meningitis cases (January 2010 - April 2021).
• Assessment of seizure development in patients, comparing those who received ASM prophylaxis with those who did not.
• Evaluation of the timing of ASM administration relative to seizure occurrence.

Main Results:

• 24.4% of 86 patients developed acute symptomatic seizures, often before hospital admission.
• Seizure development was linked to increased need for intubation, ICU admission, longer hospital stays, and higher risk of death/disability.
• ASM prophylaxis (64/74 patients) was associated with significantly lower seizure incidence (9.4% vs. 40%) and was most effective when given within 4 hours of admission.

Conclusions:

• Seizure development is a common and serious complication of pneumococcal meningitis.
• Antiseizure medication prophylaxis shows promise in preventing seizures and may improve prognosis.
• Early administration of ASM prophylaxis could mitigate severe outcomes associated with pneumococcal meningitis.